2 terminated, 1 completed. 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Completed 1 |
Follow Ambrisentan 5 mg: new trials by email Literature Review of Ambrisentan 5 mg trials Research Report on Ambrisentan 5 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Ambrisentan 5 mg - Hypertension | Phase 3 | Terminated | GlaxoSmithKline | 19 | 2014-01-23 | 2017-09-11 |
| A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude Aminophylline 400 mg, Ambrisentan 5 mg, Placebo - Acute Mountain Sickness and Fatigue | Phase 1 | Completed | Robert J Noveck, M.D. | 92 | 2013-09-01 | 2015-11-13 |
| Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Ambrisentan 5 mg, Placebo - Hypertension | Phase 3 | Terminated | GlaxoSmithKline | 33 | 2013-09-01 | 2017-03-06 |
Hypertension (2) · Altitude Sickness (1) · Fatigue (1)
GlaxoSmithKline (2) · Robert J Noveck, M.D. (1)
United States (3) · Argentina (2) · Austria (2) · Canada (2) · China (2) · Czechia (2) · Germany (2) · Israel (2) · Japan (2) · Mexico (2) · Netherlands (2) · Russia (2) · Saudi Arabia (2) · South Korea (2) · Spain (2)
Claude A Piantadosi, MD (1) · Robert J Noveck, MD, PhD (1) · Thies Schroeder, PhD (1)